Chemotherapy-induced Neuropathy
Conditions
Brief summary
Chimiotherapy produces neuropathies injuries to 30% to 70% cases. A third of those patients keeps suffering from this side effects disabilities and their quality of life is seriously affected. Hypnosis, as a non-invasive tool without physical side effects, might be used to relieve them. the purpose of this trial based on our own experience, is to demonstrate the value of using hypnosis and self-hypnosis in chimiotherapy- induced chronic neuropathies. The aim will be to sustainably improve the quality of life by expanding self-management of pain and motor function side effect.
Interventions
BEHAVIORALNurse interview
Personal interview with nurses to evaluate the relief of neuropathic pains with the reference treatment. (If necessary send to the medical team ) It's a listening time around neuropathic pain which altered the quality of life.
BEHAVIORALHypnosis sessions
Hypnosis sessions with a nurse or psychologist, with deepening sessions to facilitate self-hypnosis learning.
Sponsors
University Hospital, Strasbourg, France
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Minimum age :18 years * Chemiotherapy- induced chronic neuropathies for at least 2 months with a DN4 score \>4 * Failure of classic treatment used to relief neuropathic * Having stopped chemotherapy treatment and being in complete or partial response or in tumoral stability * Without any planed chemiotherapy during the study * Having signed a written informed consent. * French efficient understanding * With health insurance coverage * availability during all the study * With efficient contraception for women of childbearing age
Exclusion criteria
* No participation to another study at the same time * Suffering from neuropathy before having chemotherapy * Other disease that may cause neuropathy * deafness * Any medicine that could cause neuropathy * Neurological or psychiatrical disease past or present * Mental retardation * Allergy to EMG's electrodes * Unable to consent, under tutelage or curatorship or judiciary safeguard * Pregnant or nursing woman
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Measure at 12 weeks (D84) benefits of hypnosis and self-hypnosis on the sensitive dimension of the quality of life of patients with chronic peripheral neuropathies arising from a cancer chemotherapy and inadequately relief with reference treatments. | Day 84 |
Secondary
| Measure | Time frame |
|---|---|
| Measure at 12 weeks (D84) benefits of hypnosis and self-hypnosis on the loss of autonomy of patients with chronic peripheral neuropathies arising from a cancer chemotherapy and inadequately relief with reference treatments. | Day 84 |
| Measure benefits of hypnosis on the neuropathic pain intensity | Day 28, day 56 and Day 84. |
| Measure benefits of hypnosis on a psychotropic treatments | Day 0, Day 28, day 56 and Day 84. |
| Measure benefits of hypnosis on analgesic treatments | Day 0, Day 28, day 56 and Day 84. |
| Measure at 12 weeks (D84) benefits of hypnosis and self-hypnosis on the motor dimension of the quality of life of patients with chronic peripheral neuropathies arising from a cancer chemotherapy and inadequately relief with reference treatments. | Day 84 |
| Measure benefits of hypnosis on electrophysiological abnormalities related to neuropathy | Day 84 |
| Measure benefits of hypnosis on self- hypnosis in the experimental group | Day 28, Day 56 and D84 |
| Evaluate the safety in the two arms, due to hypnosis adverse effects, to pain treatment or another reason | Day 0, Day 28, Day 56, Day 84 and in case of serious adverse event |
| Measure benefits of hypnosis on tendon reflexes, deep and superficial sensitivity, muscular strength | Day 84 |
Countries
France
Contacts
Primary ContactAnne Laudamy
Backup Contactanatta Razafimanantsoa
Outcome results
None listed